Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE131984_JQ1

Dataset summary for GSE131984_JQ1

Datast information	Dataset	GSE131984_JQ1
	PMID	32393766
	Raw data ID/link	PRJNA545508
	Organism	Homo sapiens
	Source	SUM159 cell line
	Tissue	Cell line
	Cancer type level1	Breast cancer
	Cancer type level2	Triple-negative breast cancer (TNBC)
	Regimen	JQ1
	Drug type	Targeted therapy
	Sample size	resistant 2, sensitive 2
	Cell number	2626
	Extract protocol	10x genomics
	Data processing	CellRanger 2.1.0
	Public date	Public on Apr 08, 2021
	Description	This dataset has 1 cell line with 2 sensitive pre-treatment samples and 2 resistant post-treatment samples.

Top

Drug summary for GSE131984_JQ1

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"JQ1" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
MDH1	ENSG00000014641	-0.432005	5.16e-21	8.35e-17	0.642	0.752	Malignant cells	NA
SLBP	ENSG00000163950	-0.432042	3.19e-30	5.17e-26	0.592	0.753	Malignant cells	NA
ARF1	ENSG00000143761	-0.432122	0.00e+00	0.00e+00	0.955	0.987	Malignant cells	NA
PRDX2	ENSG00000167815	-0.432332	1.65e-42	2.67e-38	0.914	0.971	Malignant cells	NA
NDUFS6	ENSG00000145494	-0.432726	0.00e+00	0.00e+00	1	0.999	Malignant cells	NA
PIN4	ENSG00000102309	-0.433057	3.50e-36	5.66e-32	0.525	0.708	Malignant cells	NA
CDCA4	ENSG00000170779	-0.433238	2.34e-29	3.79e-25	0.486	0.663	Malignant cells	NA
PEF1	ENSG00000162517	-0.433537	1.40e-44	2.24e-40	0.296	0.537	Malignant cells	NA
AIMP1	ENSG00000164022	-0.433713	9.73e-34	1.58e-29	0.652	0.781	Malignant cells	NA
NDUFS3	ENSG00000285387	-0.434041	4.54e-40	7.35e-36	0.728	0.846	Malignant cells	NA
LINC00152	NA	-0.434199	1.88e-40	3.05e-36	0.847	0.915	Malignant cells	NA
CAPN2	ENSG00000162909	-0.434913	2.80e-44	4.50e-40	0.865	0.948	Malignant cells	NA
BAZ1A	ENSG00000198604	-0.435111	1.33e-38	2.15e-34	0.461	0.681	Malignant cells	NA
MKI67	ENSG00000148773	-0.435149	1.60e-29	2.59e-25	0.578	0.786	Malignant cells	NA
C4orf27	NA	-0.435154	4.38e-36	7.10e-32	0.399	0.615	Malignant cells	NA
IFI27	ENSG00000275214	-0.435238	3.33e-41	5.39e-37	0.638	0.834	Malignant cells	NA
PDCD5	ENSG00000105185	-0.435321	0.00e+00	0.00e+00	0.997	1	Malignant cells	NA
PUF60	ENSG00000274081	-0.436356	4.81e-38	7.79e-34	0.523	0.727	Malignant cells	NA
WTAP	ENSG00000146457	-0.436482	7.56e-39	1.22e-34	0.709	0.847	Malignant cells	NA
MVB12A	ENSG00000141971	-0.436519	8.97e-44	1.45e-39	0.541	0.749	Malignant cells	NA
TMEM167A	ENSG00000174695	-0.436528	0.00e+00	0.00e+00	0.931	0.985	Malignant cells	NA
GTF3A	ENSG00000122034	-0.436857	0.00e+00	0.00e+00	0.993	0.996	Malignant cells	NA
ARPC5	ENSG00000162704	-0.437108	0.00e+00	0.00e+00	0.912	0.969	Malignant cells	NA
SRPX	ENSG00000101955	-0.437523	1.18e-37	1.91e-33	0.281	0.502	Malignant cells	NA
GNL2	ENSG00000134697	-0.437733	1.93e-39	3.13e-35	0.369	0.602	Malignant cells	NA
SPG20	NA	-0.438002	8.43e-41	1.37e-36	0.389	0.618	Malignant cells	NA
PHF5A	ENSG00000100410	-0.438071	2.10e-42	3.40e-38	0.465	0.691	Malignant cells	NA
TACO1	ENSG00000136463	-0.438181	1.40e-45	3.04e-41	0.335	0.587	Malignant cells	NA
TXNDC9	ENSG00000115514	-0.438254	1.33e-33	2.16e-29	0.422	0.622	Malignant cells	NA
ARL6IP5	ENSG00000144746	-0.438334	2.60e-34	4.21e-30	0.769	0.87	Malignant cells	NA
PDCD2	ENSG00000071994	-0.439082	2.80e-45	4.06e-41	0.829	0.927	Malignant cells	NA
NME4	ENSG00000103202	-0.439092	8.38e-26	1.36e-21	0.391	0.558	Malignant cells	NA
MRPL14	ENSG00000180992	-0.439283	0.00e+00	0.00e+00	0.987	0.995	Malignant cells	NA
PPIH	ENSG00000171960	-0.43993	1.90e-37	3.08e-33	0.458	0.666	Malignant cells	NA
DNAJC7	ENSG00000168259	-0.440133	4.49e-38	7.27e-34	0.648	0.809	Malignant cells	NA
CAV1	ENSG00000105974	-0.4403	0.00e+00	7.15e-44	0.987	0.995	Malignant cells	NA
C21orf59	NA	-0.440625	1.96e-37	3.17e-33	0.382	0.601	Malignant cells	NA
CCDC34	ENSG00000109881	-0.440702	3.11e-42	5.04e-38	0.68	0.843	Malignant cells	NA
RAB2A	ENSG00000104388	-0.44071	3.99e-42	6.46e-38	0.775	0.892	Malignant cells	NA
GPX8	ENSG00000164294	-0.440748	1.18e-31	1.91e-27	0.56	0.714	Malignant cells	NA
CLTB	ENSG00000175416	-0.44076	0.00e+00	2.10e-44	0.909	0.968	Malignant cells	NA
CDKN3	ENSG00000100526	-0.441012	3.07e-41	4.97e-37	0.802	0.943	Malignant cells	NA
SUB1	ENSG00000113387	-0.441523	0.00e+00	0.00e+00	1	1	Malignant cells	NA
PRRC2C	ENSG00000117523	-0.441654	0.00e+00	1.16e-42	0.788	0.907	Malignant cells	NA
NASP	ENSG00000132780	-0.441987	6.52e-34	1.06e-29	0.602	0.769	Malignant cells	NA
PYURF	ENSG00000145337	-0.442088	0.00e+00	0.00e+00	0.956	0.992	Malignant cells	NA
CHCHD1	ENSG00000172586	-0.442458	0.00e+00	5.61e-45	0.776	0.902	Malignant cells	NA
NUP37	ENSG00000075188	-0.44306	3.23e-36	5.24e-32	0.263	0.479	Malignant cells	NA
MRPL9	ENSG00000143436	-0.443272	2.46e-42	3.99e-38	0.555	0.744	Malignant cells	NA
ACTR3	ENSG00000115091	-0.443478	1.33e-43	2.14e-39	0.744	0.882	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	3.50e-13	1.70e-12	1868	781	122	23467	Malignant cells	ATG5,AURKA,BAX,BCAT1,BIRC5,CTSL,CDCP1,CDK4,CDKN1A,CFLAR,CIAPIN1,DCTD,DUSP6,FADD,HMGA1,HMGB1,ID1,IFI27,IL6,ISG15,JUN,MAGEA6,MAGEA12,MYC,NFKB1,PARP1,PPARG,SHC1,SOX9,SPRY2,STMN1,TGFB1,PBK,TYMS,SLC25A5,AIFM1,AKAP12,AR,ANXA1,ATG3,BAG1,BID,HSPA5,CASP1,CAV2,CCNA2,CCNB1,CDK1,CCND1,HSPD1,COL1A1,CUL4A,DDIT3,DKK1,EGR1,HSP90B1,EPHA2,FN1,FTL,GAPDH,G6PD,GCLM,HAX1,HMGB2,HMGN5,HSPA8,EIF4A1,EIF4A3,EIF4E,NFKBIA,ITGA5,LASP1,LDHA,LRRFIP1,MTDH,MXD4,MAGEA3,MAPK3,MAP2K2,MYBL2,NQO1,PIK3R1,PDCD10,PGK1,AGPAT2,PLK1,POMP,PSMB5,PSMG2,RAP1B,RAB27A,RRM1,S100A11,SDC2,SDHB,SMC4,SOCS3,SOD2,SRSF2,TPT1,TFAM,TMED3,TNFAIP3,UBE2C,AXL,WLS,XRCC4,ENO1,GNAS,CD33,NPM1,IL7R,EIF4EBP1,RCN1,RELB,BRD2,PMVK,EBP,NUPR1,TRIB3,WTAP,ACAT2
Drug Inactivation by Structure Modification	1.60e-01	4.10e-01	1868	27	4	23467	Malignant cells	CES1,SOD2,CDA,NME1
Aberration of the Drug's Therapeutic Target	7.30e-01	1.00e+00	1868	90	6	23467	Malignant cells	CDK4,AR,MAP2K2,NPM1,COMT,AKR1B1
Irregularity in Drug Uptake and Drug Efflux	8.10e-01	1.00e+00	1868	37	2	23467	Malignant cells	SLC3A2,ABCE1
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	1868	455	15	23467	Malignant cells	ATG5,H2AFY,IL6,PPARG,SPRY2,TRIP6,TYMS,PMAIP1,GAPDH,MAPK3,SMC4,MALAT1,GDI2,PPP1R15A,MT-CO2

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	metacluster_22.12	4.41	0.0782	NFE2; NFE2L1 (directAnnotation).	Malignant cells
	metacluster_22.25	4.07	0.0747	NFE2L2 (directAnnotation).	Malignant cells
	metacluster_187.7	4.06	0.0746	FEZF1; FEZF1; ZNF384; ZNF384; ZNF384 (directAnnotation). OVOL2; OVOL3; PEG3; PLAG1; PLAGL1; PLAGL2; REST; SCAND1; ZKSCAN2; ZNF131; ZNF174; ZNF18; ZNF202; ZNF274; ZNF444; ZNF446; ZNF496; ZNF518A; ZNF518B; ZNF576; ZNF641; ZNF770; ZSCAN1; ZSCAN18; ZSCAN29; ZSCAN32; ZSCAN5A; ZSCAN5B; ZSCAN5C (inferredBy_Orthology).	Malignant cells
	metacluster_30.4	3.94	0.0733	BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation).	Malignant cells
	metacluster_130.3	3.86	0.0725	ZNF492; ZNF492 (directAnnotation). OVOL2; OVOL3; PEG3; PLAG1; PLAGL1; PLAGL2; REST; SCAND1; ZKSCAN2; ZNF131; ZNF174; ZNF18; ZNF202; ZNF274; ZNF444; ZNF446; ZNF496; ZNF518A; ZNF518B; ZNF576; ZNF641; ZNF770; ZSCAN1; ZSCAN18; ZSCAN29; ZSCAN32; ZSCAN5A; ZSCAN5B; ZSCAN5C (inferredBy_Orthology).	Malignant cells
	tfdimers__MD00339	3.73	0.0711	HMGA1; HMGA2; TFAP2C (directAnnotation).	Malignant cells
	metacluster_22.29	3.73	0.0711	NFE2 (directAnnotation).	Malignant cells
	swissregulon__mm__Atf2	3.71	0.0709	ATF2 (inferredBy_Orthology).	Malignant cells
	metacluster_22.32	3.65	0.0703	NFE2L2 (directAnnotation).	Malignant cells
	metacluster_22.17	3.55	0.0692	NFE2 (directAnnotation).	Malignant cells

Page: 1 2 3

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	6.8	0.0628	ETS2 (directAnnotation).	Malignant cells
	metacluster_191.3	6.27	0.0597	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_166.4	6.08	0.0586	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_191.2	5.9	0.0575	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_166.2	5.6	0.0557	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	5.6	0.0557	ETV5; HOXA2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	5.52	0.0552	ELK3; FOXO1 (directAnnotation).	Malignant cells
	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	5.27	0.0538	ELF1; MEIS1 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	5.17	0.0532	ELF2 (directAnnotation).	Malignant cells
	transfac_pro__M04826	5.1	0.0527	EP300 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5 6

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
EGR1	metacluster_34.3	up	Malignant cells	NA
SREBF1	metacluster_57.3	up	Malignant cells	NA
HES6	metacluster_57.3	up	Malignant cells	NA
ETV4	metacluster_191.3	down	Malignant cells	NA
ETV4	metacluster_166.4	down	Malignant cells	NA
ETV4	metacluster_166.2	down	Malignant cells	NA
ETV4	metacluster_138.2	down	Malignant cells	NA
ETV4	hdpi__ETV4	down	Malignant cells	NA
ETV4	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	down	Malignant cells	NA
ETV4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	down	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."